English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

CLL: chronic lymphocytic leukemia PR: pityriasis rosea EGFR: epidermal growth factor receptor PDGFR: platelet-derived growth factor receptor I brutinib, a Bruton tyrosine kinase inhibitor, is a new oral agent approved for the treatment of chronic lymphocytic leukemia (CLL). Ibrutinib is well-tolerated, with the majority of its adverse events within grade 1 or 2 severity. The most common nonhematologic side effects are diarrhea, arthralgia, rash, and brittle nails. Three subtypes of ibrutinib-related dermatitis have been reported in the literature: 1) asymptomatic nonpalpable petechial rash, 2) leukocytoclastic vasculitiselike pruritic violaceous palpable purpura, and 3) painless nonpruritic edematous papules with centripetal spread. We report a previously undescribed case of a pityriasis rosea (PR)elike dermatitis associated with the use of ibrutinib.

Ibrutinib-associated pityriasis rosea–like rash